Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | JAK1 | P23458 | 3/20 | 0.34 |
| ▸ | TYK2 | P29597 | 3/20 | 0.34 |
| ▸ | JAK3 | P52333 | 3/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | GRK2 | P25098 | 1/20 | 0.34 |
| ▸ | GRK5 | P34947 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.32 |
| ▸ | MAP4K3 | Q8IVH8 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986316 | 1.00 | JAK2 (0.34) | JAK2JAK1TYK2JAK3KCNN4 | |
| SCHEMBL12924161 | 0.88 | BMPR1A (0.43) | KCNN4LRRK2GRK2GRK5MET | |
| SCHEMBL984510 | 0.88 | BMPR1A (0.40) | KCNN4GRK2GRK5METALK | |
| SCHEMBL986488 | 0.86 | MET (0.40) | KCNN4LRRK2GRK2GRK5MET | |
| SCHEMBL12924158 | 0.86 | MET (0.45) | KCNN4LRRK2GRK2GRK5MET | |
| SCHEMBL985945 | 0.82 | KDR (0.40) | KCNN4LRRK2METMAPK1 | |
| SCHEMBL985199 | 0.81 | AXL (0.38) | KCNN4LRRK2MET | |
| SCHEMBL986251 | 0.81 | KCNN4 (0.41) | KCNN4 | |
| SCHEMBL986260 | 0.81 | MET (0.47) | GRK2GRK5METALKMAP4K3 | |
| SCHEMBL986886 | 0.81 | MET (0.47) | GRK2GRK5METALKMAP4K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101479255-B | C-MET protein kinase inhibitors for the treatment of proliferative disorders | VERTEX PHARMA | 2013-05-01 | — | — | CN | claimed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | claimed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | claimed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | claimed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | claimed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | claimed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | JAK2 33/4885JAK1 133/4885TYK2 948/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | JAK2 33/4885JAK1 133/4885TYK2 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.